PE20230108A1 - Variantes de anticuerpos caninos - Google Patents
Variantes de anticuerpos caninosInfo
- Publication number
- PE20230108A1 PE20230108A1 PE2022002420A PE2022002420A PE20230108A1 PE 20230108 A1 PE20230108 A1 PE 20230108A1 PE 2022002420 A PE2022002420 A PE 2022002420A PE 2022002420 A PE2022002420 A PE 2022002420A PE 20230108 A1 PE20230108 A1 PE 20230108A1
- Authority
- PE
- Peru
- Prior art keywords
- igg
- canine
- variants
- substitution
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011453P | 2020-04-17 | 2020-04-17 | |
| PCT/US2021/027836 WO2021212081A1 (en) | 2020-04-17 | 2021-04-16 | Canine antibody variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230108A1 true PE20230108A1 (es) | 2023-01-25 |
Family
ID=75888187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002420A PE20230108A1 (es) | 2020-04-17 | 2021-04-16 | Variantes de anticuerpos caninos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230242635A1 (https=) |
| EP (1) | EP4136106A1 (https=) |
| JP (1) | JP2023522029A (https=) |
| KR (1) | KR20230005156A (https=) |
| CN (1) | CN115996949A (https=) |
| AU (1) | AU2021256056A1 (https=) |
| BR (1) | BR112022020944A2 (https=) |
| CA (1) | CA3175921A1 (https=) |
| CL (2) | CL2022002857A1 (https=) |
| CO (1) | CO2022014695A2 (https=) |
| EC (1) | ECSP22080846A (https=) |
| IL (1) | IL297287A (https=) |
| MX (1) | MX2022012866A (https=) |
| PE (1) | PE20230108A1 (https=) |
| PH (1) | PH12022552742A1 (https=) |
| TW (1) | TW202204403A (https=) |
| WO (1) | WO2021212081A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| BR112020002871A2 (pt) | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | variantes fc de igg para uso veterinário |
| US11542333B2 (en) | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| US11434276B2 (en) | 2020-05-11 | 2022-09-06 | Invetx, Inc. | Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use |
| EP4178977A1 (en) | 2020-07-10 | 2023-05-17 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| IL301413A (en) * | 2020-09-28 | 2023-05-01 | Zoetis Services Llc | Canine antibody variants |
| KR20250026186A (ko) * | 2022-06-21 | 2025-02-25 | 조에티스 서비시즈 엘엘씨 | 갯과 항체 돌연변이체 |
| JP2026508096A (ja) | 2023-01-20 | 2026-03-10 | ゾエティス・サービシーズ・ユーケー・リミテッド | 治療抗体 |
| WO2025166165A1 (en) * | 2024-02-01 | 2025-08-07 | Zoetis Services, Llc | Compositions and methods for modifying antibody effector functions |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| KR20070057839A (ko) | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US9505829B2 (en) | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| RS61723B1 (sr) * | 2011-02-04 | 2021-05-31 | Zoetis Services Llc | Imunogenične bordetella bronchiseptica kompozicije |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
| CN114773470A (zh) * | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| KR20230079500A (ko) * | 2015-09-18 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8에 결합하는 항체 및 그의 사용 |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| TWI693940B (zh) * | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Ｉｌ-８相關疾病之治療用或預防用組成物 |
| WO2018073185A1 (en) * | 2016-10-17 | 2018-04-26 | Vetoquinol Sa | Modified antibody constant region |
| WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| CN113194984A (zh) * | 2018-10-18 | 2021-07-30 | 金德雷德生物科学股份有限公司 | 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体 |
| US11542333B2 (en) * | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| US20220169740A1 (en) * | 2019-03-20 | 2022-06-02 | Kindred Biosciences, Inc. | NGF Antagonists for Medical Use |
| IL301413A (en) * | 2020-09-28 | 2023-05-01 | Zoetis Services Llc | Canine antibody variants |
| WO2022165067A2 (en) * | 2021-01-28 | 2022-08-04 | Zoetis Services Llc | Mutations in canine antibody constant regions |
-
2021
- 2021-04-16 CN CN202180028973.4A patent/CN115996949A/zh active Pending
- 2021-04-16 EP EP21724863.2A patent/EP4136106A1/en active Pending
- 2021-04-16 JP JP2022562645A patent/JP2023522029A/ja active Pending
- 2021-04-16 IL IL297287A patent/IL297287A/en unknown
- 2021-04-16 MX MX2022012866A patent/MX2022012866A/es unknown
- 2021-04-16 PE PE2022002420A patent/PE20230108A1/es unknown
- 2021-04-16 CA CA3175921A patent/CA3175921A1/en active Pending
- 2021-04-16 AU AU2021256056A patent/AU2021256056A1/en active Pending
- 2021-04-16 KR KR1020227035765A patent/KR20230005156A/ko active Pending
- 2021-04-16 BR BR112022020944A patent/BR112022020944A2/pt unknown
- 2021-04-16 US US17/918,853 patent/US20230242635A1/en active Pending
- 2021-04-16 WO PCT/US2021/027836 patent/WO2021212081A1/en not_active Ceased
- 2021-04-16 PH PH1/2022/552742A patent/PH12022552742A1/en unknown
- 2021-04-19 TW TW110113947A patent/TW202204403A/zh unknown
-
2022
- 2022-10-17 EC ECSENADI202280846A patent/ECSP22080846A/es unknown
- 2022-10-17 CL CL2022002857A patent/CL2022002857A1/es unknown
- 2022-10-18 CO CONC2022/0014695A patent/CO2022014695A2/es unknown
-
2023
- 2023-11-13 CL CL2023003377A patent/CL2023003377A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022012866A (es) | 2022-11-08 |
| US20230242635A1 (en) | 2023-08-03 |
| TW202204403A (zh) | 2022-02-01 |
| ECSP22080846A (es) | 2023-02-28 |
| KR20230005156A (ko) | 2023-01-09 |
| JP2023522029A (ja) | 2023-05-26 |
| CA3175921A1 (en) | 2021-10-21 |
| WO2021212081A1 (en) | 2021-10-21 |
| AU2021256056A1 (en) | 2022-10-20 |
| PH12022552742A1 (en) | 2024-03-25 |
| IL297287A (en) | 2022-12-01 |
| EP4136106A1 (en) | 2023-02-22 |
| BR112022020944A2 (pt) | 2022-12-27 |
| CL2023003377A1 (es) | 2024-04-19 |
| CN115996949A (zh) | 2023-04-21 |
| CO2022014695A2 (es) | 2022-10-21 |
| CL2022002857A1 (es) | 2023-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230108A1 (es) | Variantes de anticuerpos caninos | |
| PE20230348A1 (es) | Variantes de anticuerpos felinos | |
| BR112016016416A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS | |
| BR112016016411A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS | |
| MX2020009642A (es) | Anticuerpos monoclonales de interleucina-31 para uso veterinario. | |
| EA201991701A1 (ru) | Состав на основе моноклонального антитела к rsv | |
| ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
| BR112021026089A2 (pt) | Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos | |
| CO2018004090A2 (es) | Anticuerpos anti-tigit y métodos de uso | |
| BR112017006591A2 (pt) | polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico | |
| BR112018076260A2 (pt) | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina | |
| MX2021012251A (es) | Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc). | |
| NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
| BR112018000477A2 (pt) | proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural | |
| BR112022022922A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso | |
| BR112016020065A2 (pt) | sítios específicos para modificar anticorpos para fazer imunoconjugados | |
| BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado | |
| ATE452913T1 (de) | Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen | |
| EA202190264A1 (ru) | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn | |
| MX393649B (es) | Vacunas y anticuerpos contra el dengue | |
| EA201892554A1 (ru) | Мутант cd200 и его применения | |
| EA201991464A1 (ru) | АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ | |
| BR112021024938A2 (pt) | Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso | |
| ES3059248T3 (en) | Humanized anti-il17a antibody and use thereof |